Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Fosun to Start US Trial of COVID-19 Antibody Treatment

publication date: Oct 9, 2020
 | 
author/source: Richard Daverman, PhD

Fosun Pharma (SHA: 600196; HK: 02196) was granted US FDA approval to begin clinical tests of an investigational COVID-19 antibody treatment, HLX70. The trial will be conducted by Hengenix Biotech, the California arm of Fosun's biologics subsidiary, Henlius (HK: 2696). Hengenix co-developed the molecule with Sanyou Biopharma, a CRO, and Shanghai ZJ Bio-Tech. It is aimed at treating the acute respiratory distress syndrome and multiple organ failure that is associated with COVID-19.

The Phase I trial will evaluate the safety and pharmacokinetics of HLX70 in healthy volunteers. To date, Fosun has invested $2 million in the candidate, according to the company.

Henlius says it has three campuses working on developing biologics -- Shanghai, Taipei and the Hengenix site in Milpitas, California.

In March of this year, Fosun announced a $135 million agreement to develop and commercialize an mRNA COVID-19 vaccine in China that was developed by BioNTech (NSDQ: BNTX) of Germany. Pfizer (NYSE: PFE) acquired US rights to the same vaccine. Fosun paid $50 million upfront  and will make up to $85 million in milestone payments for the China rights. 

See our other articles on Fosun Pharma and Henlius.

Disclosure: none.

 

 

 

 


 

Share this with colleagues:

 

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021